ENFUEGO THERAPEUTICS

Enfuego Therapeutics is a company that merges science and technology to create RNA interference (RNAi)-based drugs for treating cancer. The company was founded by Chad Pecot in 2019 and is headquartered in Pittsboro, North Carolina.

#People #More

ENFUEGO THERAPEUTICS

Industry:
Biotechnology Health Care Therapeutics

Founded:
2019-02-01

Address:
Pittsboro, North Carolina, United States

Country:
United States

Total Employee:
1+

Status:
Active

Contact:
615-305-3955


Current Employees Featured

chad-pecot_image

Chad Pecot
Chad Pecot Founder and CEO @ Enfuego Therapeutics
Founder and CEO
2019-02-01

Founder


chad-pecot_image

Chad Pecot

More informations about "Enfuego Therapeutics"

Enfuego Therapeutics 2025 Company Profile: Valuation, Funding ...

Enfuego Therapeutics General Information Description. Operator of a biotech company intended to treat lung, pancreatic and colon cancers. The company is developing RNA interference …See details»

EnFuego Therapeutics - LinkedIn

EnFuego Therapeutics | 545 followers on LinkedIn. EnFuego Therapeutics is pioneering tumor-selective, mutant-specific RNAi molecules to solve cancer’s greatest challenges.See details»

Enfuego Therapeutics - Contacts, Employees, Board Members, …

Enfuego Therapeutics is a company that merges science and technology to create RNA interference (RNAi)-based drugs for treating cancer. ... Experience the new Crunchbase, …See details»

Enfuego Therapeutics Inc. - VentureRadar

Enfuego Therapeutics' novel RNA interference-(RNAi)-based and antisense oligo therapeutics are intended to treat cancer. We’re going after the big players in cancer, trying to develop drugs …See details»

Enfuego Therapeutics - Crunchbase

Enfuego Therapeutics is a company that merges science and technology to create RNA interference (RNAi)-based drugs for treating cancer. Search Crunchbase. Start Free Trial . …See details»

Enfuego Therapeutics, Inc. - Drug pipelines, Patents, Clinical trials ...

Jan 23, 2025 Explore Enfuego Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 literature, Disease Domain:Neoplasms, Technology Platform:siRNA, …See details»

Enfuego Therapeutics | CipherBio

Enfuego Therapeutics is a company that merges science and technology to create RNA interference (RNAi)-based drugs for treating cancer. See all funding and science results with …See details»

ENFUEGO THERAPEUTICS - Enfuego Therapeutics, Inc. Trademark …

Mark For: ENFUEGO THERAPEUTICS® trademark registration is intended to cover the categories of scientific and technological services, namely, scientific research, design, analysis …See details»

Enfuego Therapeutics, Inc. (Enfuego Therapeutics, Inc.) - 药物管线_ …

Oncogenic mutations in the KRAS gene are well-established drivers of cancer. While the recently developed KRAS G12C inhibitors offer a targeted KRAS therapy and have shown success in …See details»

Enfuego Therapeutics Inc. Company Profile - Dun & Bradstreet

Find company research, competitor information, contact details & financial data for Enfuego Therapeutics Inc. of Pittsboro, NC. Get the latest business insights from Dun & Bradstreet.See details»

Enfuego Therapeutics Inc. | North Carolina Biotech Center

Enfuego Therapeutics Inc. Enfuego Therapeutics Inc. Enfuego Therapeutics is developing novel RNA interference-(RNAi)-based and antisense oligo therapeutics. Company Location. 5151 …See details»

Firm - SBIR

EnFuego Therapeutics, Inc. (EFTX) was founded to address the growing number of “undruggable” targets in cancer using RNA interference (RNAi)-based therapeutics. RNAi is particularly …See details»

Chad Pecot: EnFuego Therapeutics is making a new generation of …

Oct 6, 2024 Chad Pecot, CEO of EnFuego Therapeutics, shared on X: ”Coming out of ‘stealth mode’ today with my hair on fire. EnFuego Therapeutics is making a new generation of RNA …See details»

UNC Innovation & Entrepreneurship - Innovate Carolina

Mar 16, 2020 In launching EnFuego Therapeutics, Pecot used innovation and entrepreneurship resources available at Carolina to develop his startup journey, including KickStart Venture …See details»

RePORT 〉 RePORTER

Awardee Organization ENFUEGO THERAPEUTICS INC. Description. Abstract Text. Project Summary The proto-oncogene KRAS is one of the most critical genes in cancer, yet, as a drug …See details»

Ligand-Directed KRAS G12V Mutant-Specific Therapeutics

Itself to be widely regarded as “undruggable”. EnFuego Therapeutics, Inc. (EFTX) was founded to address the growing number of “undruggable” targets in cancer using RNA interference (RNAi) …See details»

Development of EFTX-001 to target KRAS mutations in cancer

Jun 1, 2020 We have established a C Corporation, EnFuego Therapeutics, Inc. to address the growing number of ?undruggable? targets in cancer by using RNA interference (RNAi)-based …See details»

Fired Up for RNA - UNC Research Stories

Jan 21, 2025 Pecot’s engineered RNA and proteins are fueling his startup company, EnFuego Therapeutics, which he founded in 2019. He hopes to spend the next year conducting safety …See details»

EFTX-001 - Drug Targets, Indications, Patents - Synapse - Patsnap

EFTX-001, Initially developed by Enfuego Therapeutics, Inc., Now, its global highest R&D status is Discovery, Therapeutic Areas: Neoplasms,Respiratory Diseases ...See details»

Nutcracker Therapeutics CEO Dr. Igor Khandros Retires as …

23 hours ago EMERYVILLE, Calif., March 26, 2025--(BUSINESS WIRE)--Nutcracker Therapeutics, Inc., a contract, research, development and manufacturing organization …See details»